Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials
- PMID: 22257045
- DOI: 10.1111/j.1742-1241.2011.02837.x
Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials
Abstract
To determine the efficacy of teriparatide supplementation for improving bone mineral density (BMD) and fracture risk in postmenopausal osteoporosis and if effects vary with factors. We identified eight randomised controlled trials (n = 2388) using electronic databases, supplemented by a hand-search of the reference lists. All trials aimed to evaluate the efficacy of daily subcutaneous teriparatide injection in postmenopausal osteoporosis. The main outcomes were fracture risk and percentage change of BMD from baseline. Data were pooled by employing a random-effect model. In trials that reported BMD as an outcome, treatment was associated with an increase of bone mass of 8.14% [95% confidence interval (CI): 6.72-9.55%; eight trials, n = 2206] in spine and 2.48% (95% CI: 1.67-3.29%; seven trials, n = 1303) at the hip. In trials that reported fracture as an outcome, treatment was associated with a 70% risk reduction in vertebral fractures (risk ratio 0.30, 95% CI: 0.21-0.44; three trials, n = 1452) and 38% risk reduction in non-vertebral fractures (risk ratio 0.62, 95% CI: 0.44-0.87; three trials, n = 1842). The PTH treatment with total calcium intake more than 1500 mg was related to a significant increase in BMD gains at total hip (1.40% vs. 3.72%; p = 0.004). However, long-term duration did not appear to contribute to differences in responsiveness to teriparatide. Evidence supports the use of teriparatide in treatment of women with postmenopausal osteoporosis who are at risk for fracture. Further studies directly comparing concurrent therapy and calcium supplement with long-term duration are warranted.
© 2012 Blackwell Publishing Ltd.
Comment in
-
ACP Journal Club. Review: teriparatide reduces fractures in postmenopausal women with osteoporosis.Ann Intern Med. 2012 Sep 18;157(6):JC3-4. doi: 10.7326/0003-4819-157-6-201209180-02004. Ann Intern Med. 2012. PMID: 22986396 No abstract available.
Similar articles
-
Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.Bone. 2006 Dec;39(6):1268-75. doi: 10.1016/j.bone.2006.06.007. Epub 2006 Aug 1. Bone. 2006. PMID: 16884968 Clinical Trial.
-
Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.Bone. 2006 Aug;39(2):237-43. doi: 10.1016/j.bone.2006.02.003. Epub 2006 Mar 24. Bone. 2006. PMID: 16563890 Clinical Trial.
-
Strontium: new drug. Postmenopausal osteoporosis: too many unknowns.Prescrire Int. 2005 Dec;14(80):207-11. Prescrire Int. 2005. PMID: 16397977
-
[Teriparatide: human recombinant parathyroid hormone (1-34) as a daily subcutaneous injection].Clin Calcium. 2011 Jan;21(1):9-16. Clin Calcium. 2011. PMID: 21187589 Review. Japanese.
-
Osteoporosis: from early fracture prevention to better bone health with strontium ranelate.Rheumatology (Oxford). 2009 Oct;48 Suppl 4:iv14-9. doi: 10.1093/rheumatology/kep275. Rheumatology (Oxford). 2009. PMID: 19783589 Review.
Cited by
-
Can Over Six Months of Teriparatide Treatment Prevent the Progression of Osteoporotic Thoracolumbar Compression Fracture?Korean J Neurotrauma. 2024 Sep 19;20(3):180-190. doi: 10.13004/kjnt.2024.20.e28. eCollection 2024 Sep. Korean J Neurotrauma. 2024. PMID: 39372111 Free PMC article.
-
Immunolocalization of Enzymes/Membrane Transporters Related to Bone Mineralization in the Metaphyses of the Long Bones of Parathyroid-Hormone-Administered Mice.Medicina (Kaunas). 2023 Jun 20;59(6):1179. doi: 10.3390/medicina59061179. Medicina (Kaunas). 2023. PMID: 37374382 Free PMC article.
-
Effects of parathyroid hormone (1-34) on the regulation of the lysyl oxidase family in ovariectomized mice.RSC Adv. 2018 Aug 30;8(53):30629-30641. doi: 10.1039/c8ra04574g. eCollection 2018 Aug 24. RSC Adv. 2018. PMID: 35546858 Free PMC article.
-
Prospect of Stem Cell Therapy and Regenerative Medicine in Osteoporosis.Front Endocrinol (Lausanne). 2020 Jul 3;11:430. doi: 10.3389/fendo.2020.00430. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 32719657 Free PMC article. Review.
-
Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.Health Technol Assess. 2020 Jun;24(29):1-314. doi: 10.3310/hta24290. Health Technol Assess. 2020. PMID: 32588816 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical